Up next

Autoplay

Atogepant meets all endpoints in the Phase III ADVANCE trial for episodic migraine prevention

8 Views • 08/29/25
Share
Side Effects
Side Effects
Subscribers
0

Atogepant is an oral calcitonin gene–related peptide (CGRP) receptor antagonist, known as a gepant, currently under investigation for the preventive treatment of migraine. Jessica Ailani, MD, FAAN, Medstar Georgetown University Hospital, Washington, DC, shares the findings of the Phase III randomized, controlled ADVANCE trial (NCT03777059), evaluating the safety and efficacy of atogepant in patients with episodic migraine. Over 900 patients were randomized to receive atopgepant at one of three dose levels, or placebo, for 12 weeks. The results showed that in all 3 dose groups, atogepant met its primary outcome of a statistically significant reduction in migraine days compared to placebo. At the higher dose levels of 30mg and 60mg daily, all secondary endpoints were also met, including reduced acute medication use, reduction in physical impairment, ≥50% response rate, and improved quality of life. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.

Show more
0 Comments sort Sort By

Up next

Autoplay